Detalles de la búsqueda
1.
Ventilator-associated pneumonia and bloodstream infections in intensive care unit cancer patients: a retrospective 12-year study on 3388 prospectively monitored patients.
Support Care Cancer
; 28(1): 193-200, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31001694
2.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Ann Oncol
; 28(8): 1713-1729, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28407110
3.
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Ann Oncol
; 28(4): 882-889, 2017 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28137741
4.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Ann Oncol
; 28(5): 1078-1083, 2017 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327934
5.
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
Pediatr Blood Cancer
; 64(8)2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28111876
6.
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.
Ann Oncol
; 27(10): 1818-28, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27436850
7.
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.
Ann Oncol
; 26(6): 1223-1229, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25701455
8.
Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach.
Ann Oncol
; 25(11): 2162-2166, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25193990
9.
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.
Pharmacogenomics J
; 14(5): 424-31, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24709690
10.
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
Ann Oncol
; 24(1): 20-30, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23180113
11.
Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.
Ann Oncol
; 24(11): 2834-8, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24026540
12.
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Ann Oncol
; 23(1): 86-93, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21471564
13.
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Ann Oncol
; 23(9): 2245-2252, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22269178
14.
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Eur Respir J
; 39(1): 172-9, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21659409
15.
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.
Lancet
; 375(9722): 1267-77, 2010 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20338627
16.
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.
Ann Oncol
; 25(9): 1865-1866, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24920790
17.
Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas.
Syst Rev
; 8(1): 96, 2019 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30987679
18.
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.
Eur J Cancer
; 108: 88-96, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30648633
19.
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.
Ann Oncol
; 19(4): 787-92, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18042834
20.
[Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]. / Résection R0, seul facteur pronostique dans les amputations abdominopérinéales de rattrapage des cancers du canal anal (série consécutive de 95 patients).
J Chir (Paris)
; 145(4): 335-40, 2008.
Artículo
en Francés
| MEDLINE | ID: mdl-18955923